Clinical Trial Update: Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection [Phase 2]

View source ↗

Summary

A Phase 2 trial of bezlotoxumab for Clostridioides difficile infection examined outcomes tailored to personalized patient needs, with results posted after compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection
• Clostridioides Difficile Infection Recurrence

Drugs mentioned

• Zinplava (bezlotoxumab)

Snippet

Sponsor: Hellenic Institute for the Study of Sepsis | Conditions: Clostridioides Difficile Infection, Stool Microbiome | Phase 2 | Status: COMPLETED | Results posted: 2026-03-04